{"id":"d14d5e9a-aee8-5ed9-abde-61c47df22800","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-metabolites-outlast-the-drug","predicate":"produces","statement":"The plasma areas under the curve for the major metabolites of mebendazole, methyl 5-(alpha-hydroxybenzyl)-2-benzimidazole carbamate and 2-amino-5-benzoylbenzimidazole, were about five times that found for mebendazole itself in patients on chronic therapy, which the authors suggest results from enterohepatic recycling of these polar metabolites, and since mebendazole is also highly plasma protein bound caution should be observed in patients with liver disease, while concentrations in tissue and cyst material collected at surgery ranged from 59.5 to 206.6 nanograms per gram wet weight.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"469a318f-2a74-5b88-901f-1e779f1f032b","mechanism_event_label":"What circulates is mostly the breakdown products, and they hang around five times longer than the drug.","subject":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"object":{"id":"8e8d0bfc-e722-5d48-91a0-36e9571a0567","slug":"hydroxymebendazole","display_name":"Methyl 5-(alpha-hydroxybenzyl)-2-benzimidazole carbamate, the hydroxy metabolite","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"469a318f-2a74-5b88-901f-1e779f1f032b","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-metabolites-outlast-the-drug-event","event_type":"observed_intervention","label":"What circulates is mostly the breakdown products, and they hang around five times longer than the drug.","description":"The plasma areas under the curve for the major metabolites of mebendazole, methyl 5-(alpha-hydroxybenzyl)-2-benzimidazole carbamate and 2-amino-5-benzoylbenzimidazole, were about five times that found for mebendazole itself in patients on chronic therapy, which the authors suggest results from enterohepatic recycling of these polar metabolites, and since mebendazole is also highly plasma protein bound caution should be observed in patients with liver disease, while concentrations in tissue and cyst material collected at surgery ranged from 59.5 to 206.6 nanograms per gram wet weight.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ac186adc-be6e-52a5-b066-44e3e88692e1","slug":"aminobenzoylbenzimidazole","display_name":"2-amino-5-benzoylbenzimidazole, the decarbamoylated metabolite","entity_type_key":"small_molecule"},"role":"co_metabolite","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"adb6fad9-b59f-567b-8d4b-a200d6e3fe8b","slug":"enterohepatic-recycling","display_name":"Enterohepatic recycling","entity_type_key":"cellular_process"},"role":"proposed_cause","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"bdbde3de-00c3-526a-820f-c79a2f0dc3be","slug":"plasma-protein-binding","display_name":"Binding of the drug to plasma protein","entity_type_key":"cellular_process"},"role":"complicating_property","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"8e8d0bfc-e722-5d48-91a0-36e9571a0567","slug":"hydroxymebendazole","display_name":"Methyl 5-(alpha-hydroxybenzyl)-2-benzimidazole carbamate, the hydroxy metabolite","entity_type_key":"small_molecule"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/7094986.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd\", \"start_char\": 0, \"end_char\": 1256, \"text_sha256\": \"5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Plasma monitoring of mebendazole and its metabolites in twelve patients treated for cystic hydatid disease","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"10 milligrams per kilogram, with tissue sampled at surgery in two patients","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Twelve patients with wide between-patient variation. The enterohepatic recycling explanation is the authors’ inference from the metabolite profile.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"What circulates is mostly the breakdown products, and they hang around five times longer than the drug.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p7094986] Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. (1982). https://pubmed.ncbi.nlm.nih.gov/7094986/ DOI: 10.1007/bf00542462","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Plasma, tissue and cyst material","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"a8bb1fe7-4e49-5917-b0bb-49824347dae0","evidence_kind":"source_excerpt","locator":"Lines 446-457","start_line":446,"end_line":457,"excerpt":"### mbz-metabolites-outlast-the-drug\nThe plasma areas under the curve for the major metabolites of mebendazole, methyl 5-(alpha-hydroxybenzyl)-2-benzimidazole carbamate and 2-amino-5-benzoylbenzimidazole, were about five times that found for mebendazole itself in patients on chronic therapy, which the authors suggest results from enterohepatic recycling of these polar metabolites, and since mebendazole is also highly plasma protein bound caution should be observed in patients with liver disease, while concentrations in tissue and cyst material collected at surgery ranged from 59.5 to 206.6 nanograms per gram wet weight.\nCondition category: normal\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: What circulates is mostly the breakdown products, and they hang around five times longer than the drug.\norganism: Human\ntissue_or_cell_type: Plasma, tissue and cyst material\nexperimental_model: Plasma monitoring of mebendazole and its metabolites in twelve patients treated for cystic hydatid disease\nlimitations: Twelve patients with wide between-patient variation. The enterohepatic recycling explanation is the authors’ inference from the metabolite profile.\nexposure: 10 milligrams per kilogram, with tissue sampled at surgery in two patients\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/7094986.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd\", \"start_char\": 0, \"end_char\": 1256, \"text_sha256\": \"5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd\"}\n[mbz-p7094986] Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. (1982). https://pubmed.ncbi.nlm.nih.gov/7094986/ DOI: 10.1007/bf00542462","model_system":"Plasma monitoring of mebendazole and its metabolites in twelve patients treated for cystic hydatid disease","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p7094986] Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. (1982). https://pubmed.ncbi.nlm.nih.gov/7094986/ DOI: 10.1007/bf00542462","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}